EARNINGS & CATALYSTS · November 19, 2026
Agilent earnings preview: can lab demand sustain margin gains? — November 23, 2026
Agilent reports after close on November 23. Watch laboratory demand, profit margins without tariff refunds and how its completed Proscia acquisition shapes the new fiscal year.
| Company | Report date | Window | EPS estimate | Revenue estimate |
|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | November 23, 2026Issuer confirmed | After close | 1.73 | 1.99B |
1) When are results, and what is expected?
Agilent confirmed fiscal fourth-quarter and full-year 2026 results for November 23, 2026 after close. The quarter ended October 31. As checked November 19, the consensus is approximately $1.99 billion in sales and $1.73 in adjusted EPS, or profit per share. These are estimates, not released results. The issuer’s confirmation takes precedence over calendars that still label the date expected.
2) What matters in the business?
In fiscal 2025, Agilent generated $6.948 billion in revenue. CrossLab supplied $2.908 billion, Life Sciences and Diagnostics $2.726 billion and Applied Markets $1.314 billion. Recurring servicing and consumables can cushion uneven instrument orders. Watch whether customers’ replacement spending translates into sustained sales rather than a temporary catch-up.
3) What could change the outlook?
Third-quarter sales were $1.878 billion and adjusted EPS was $1.62, versus consensus of $1.84 billion and $1.49. The $0.06 EPS benefit from tariff refunds means the full improvement should not be extrapolated. Proscia closed on November 4, after fiscal year-end, for $240 million in cash plus up to $30 million in milestone payments. Its software complements pathology instruments, but integration costs and revenue contribution belong in the new-year discussion.
4) What do peers and risks suggest?
Waters reported $1.767 billion of third-quarter revenue and $4.10 adjusted EPS on November 3, with organic revenue growth of 9%. Its $896 million acquired-business contribution makes headline revenue growth a poor direct comparison. For Agilent, equipment budgets, trade costs and the pace of acquisition integration could challenge margins. A strong past quarter does not guarantee a favorable earnings-day stock move.
5) What should investors watch next?
Compare the November 23 results with the $1.98–$2.00 billion sales and $1.71–$1.74 adjusted EPS outlook, then focus on fiscal 2027 guidance. Shares closed at $177.33 on November 18. Recent lows around $170.50–$171.50 and highs near $180–$181.50 are reference areas, not price targets; earnings can create gaps beyond them.
6) How the business makes money
Agilent sells laboratory instruments, software, consumables and services to pharmaceutical, diagnostics and industrial customers. Its installed instrument base supports repeat purchases of supplies and maintenance.
7) What to watch
The next test is whether customer demand and operating improvements sustain profit growth without the third-quarter tariff-refund benefit. The completed Proscia purchase adds digital-pathology software and makes integration and fiscal 2027 guidance important.
8) Recently reported peers
Waters reported on November 3: organic revenue grew 9% and adjusted EPS reached $4.10. That supports a healthier laboratory-spending backdrop, but its acquired businesses contributed $896 million of sales, so total growth is not directly comparable with Agilent.
9) Risks into the report
Customers can delay equipment purchases. Tariffs, currencies and acquisition integration costs can pressure profits, while last quarter’s refunds make headline margin comparisons less straightforward.
10) Insider activity over the past three months
$0 bought and $95.97K sold in reported trades. 0% buy / 100% sell by value. 0 insiders bought only, 1 sold only, and 0 did both.